Novo Nordisk A/S has been making moves of late to expand into cardiovascular and rare diseases but has returned to its diabetes roots to license the hypoglycemia injection Zegalogue from Zealand Pharma A/S, a fellow Danish firm that has been on the rocks of late.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?